Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
Figure 2
Palivizumab indications across seasons. Indications are subcategorized into chronic lung disease (BPD/CLD, ), premature (), hemodynamically significant congenital heart disease (HSCHD, ), and “other” (). The “other” group comprises infants with serious underlying medical disorders.
